Cadrenal Therapeutics, Inc. Common Stock
Support and Resistance Levels
Past performance
News About CVKD
All events for CVKD
All deals for CVKD
Financial Ratios
Financial Statements
CVKD vs Sector & Peers
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida. Website cadrenal.com
Headquarters Ponte Vedra, FL, US